The regulators have spoken on both sides of the Atlantic. And in both cases, we have winners--and we have losers.
You can't accuse UCB of lacking nerve. The company says it's going to test its rheumatoid arthritis drug Cimzia against Abbott Laboratories' well established Humira treatment. As Reuters reports,
Belgian drugmaker UCB is spending €250 million ($333 million) on a new manufacturing plant in Switzerland to make sure it can keep up with demand for its rheumatoid arthritis and Crohn's disease
UCB could end up paying Cimzia royalties to a U.K. charitable trust. The Mathilda and Terence Kennedy Institute of Rheumatology Trust has sued the Belgian drugmaker for patent infringement in a case
Want to take the temperature of the U.K.'s National Institute for Health and Clinical Excellence? Just monitor the drugs they recommend for use by the National Health Service--and those they don't.
U.K. cost-effectiveness watchdog NICE says it's "minded not to recommended" the UCB drug Cimzia as a treatment option for rheumatoid arthritis, citing uncertainty embedded in economic models
FDA is tacking new, stronger warnings on TNF-alpha blockers. The new label language highlights an increased risk of cancer in children and adolescents who take the blockbuster meds. These drugs
UCB has gained European approval to market Cimzia to treat rheumatoid arthritis, a decision that followed the FDA's approval in May. The decision, which was widely expected, allows UCB a much broader
Belgium's UCB is riding high today after it won the FDA nod for a new indication for Cimzia as a rheumatoid arthritis remedy. Company officials and some analysts said the drug could be an
Shares of Belgium's UCB shot up after the company announced that the FDA had approved its blockbuster rheumatoid arthritis drug Cimzia. The drug, which the patient can inject himself using a